On June 3rd S.P.E. established a new European legal entity in Milano named Summit Pharmaceuticals Europe S.r.l. We are glad to inform that a cross-border merger of old Summit Pharmaceuticals Europe Limited (in UK) into new Summit Pharmaceuticals Europe S.r.l. (in Italy) is currently on going and is expected to become effective on 30th November 2020. Directors-ReportDownload...

As the C-19 outbreak continues to spread across in Northern Italy, SPE Group companies are working at home. If you send us anything by post, courier or fax, in the current circumstances, we cannot give assurance that this will be received or dealt with. Also note that call forwarding on our desk phones may not work, too. For urgent matters please send email to:  spe-pharma@sumitomocorp.com Sorry for the inconvenience. Many thanks for your co-operation and...

As annual appointment, SPE will be present at DCAT 2020 – MARCH 23 – 26, 2020 – in New York City, NY. We are glad to welcome you at our suite #15D at “the Kimberly Hotel” 145 East 50th Street, New York, 10022. We will be pleased to give any information about the companies, products and services we can provide and to meet potential partners for new collaborations and challenges Please contact us by e-mail to request a meeting: 📧...

Summit Pharmaceuticals Europe closed  a partnership with the Canadian company CPL for the promotion of their PLASTIBASE Hydrocarbon Gel. PLASTIBASE is a homogenous, soft, colourless, stainless, odourless and non-irritating ointment base that possesses pharmaceutical product characteristics superior to white petrolatum (USP): -More stable viscosity over a wide temperature range -Superior release of active ingredients -Better and easier spreadability -Better extrusion In case of interest in PLASTIBASE Hydrocarbon Gel please...

Summit Pharmaceuticals Europe closed  in February  2018 a partnership with the Czech company InStar Technologies for the promotion of their innovative and proprietary drug delivery carrier InStrip™ based on a nanotechnology. InStar’s  goal is to bring new transmucosal administration of drugs that are still available only by injections. InStrip™ technology provides all the benefits associated with submucosal drug delivery and with a broader range of drug candidates like peptides, proteins, hormones, enzymes or vaccines, stabilization of such kind of substances in room temperature, protection of API against saliva, increase solubility and bioavailability, lead the pharmacokinetics from fast to sustained etc.  In case of interest in InStrip™ technology please...